<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853161</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-17-0131-CTIL</org_study_id>
    <nct_id>NCT03853161</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Cannula Versus Nasal Intermittent Positive Pressure (NIPPV) in Preterm Infants</brief_title>
  <acronym>VAPORAM</acronym>
  <official_title>A Multicenter Randomized Controlled Trial Comparing High Flow Nasal Cannula and NIPPV in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effectiveness of Heated Humidified High Flow Nasal
      Cannula (HHHFNC) versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) in
      preventing intubation when used as primary respiratory support for Respiratory Distress
      Syndrome (RDS) or post extubation in preterm infants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient population will include preterm infants born at 24 - 36+6 weeks of gestation who are
      candidates for non-invasive respiratory support post extubation or as primary respiratory
      support after birth. They will be will be randomized to 2 groups: Heated Humidified High Flow
      Nasal Cannula (HHHFNC) and Nasal Intermittent Positive Pressure Ventilation (NIPPV).

      This will be a prospective unblinded randomized controlled study, designed as a
      non-inferiority trial.

      Primary outcome: The primary outcome will be rate of treatment failure (need for intubation)
      within 7 days of starting the study treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of intubation within 7 days of starting the study treatment</measure>
    <time_frame>one week</time_frame>
    <description>Failure of non invasive support by criteria of pH, blood carbon dioxide level, oxygen requirements or apneas</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Preterm Infant</condition>
  <arm_group>
    <arm_group_label>Vapotherm arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preterm infants in this arm will be given respiratory support of heated humidified high flow via Precision Flow Vapotherm, Exeter, USA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIPPV arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preterm infants in this arm will be given respiratory support of Nasal Intermittent Positive Pressure Ventilation via the Leoni Plus neonatal ventilator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vapotherm</intervention_name>
    <description>A form of non invasive ventilation used in newborns</description>
    <arm_group_label>Vapotherm arm</arm_group_label>
    <other_name>Heated Humidified High Flow Nasal Cannula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NIPPV</intervention_name>
    <description>A form of non invasive ventilation used in newborns</description>
    <arm_group_label>NIPPV arm</arm_group_label>
    <other_name>Nasal Intermittent Positive Pressure Ventilation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants born at 24-27+6 weeks of gestation and up to 28 days of life who are extubated
             for the first time after birth or immediately after surfactant administration via
             (intubation-surfactant-extubation) INSURE or (minimally invasive surfactant therapy)
             MIST procedures.

          -  Infants born at 28-36+6 weeks of gestation and up to 28 days of life who are
             candidates for non-invasive support either as a primary modality after birth or post
             extubation.

          -  Signed parental informed consent by one of the parents

        Exclusion Criteria:

          -  Infants who are unlikely to survive the immediate postnatal period or who have
             significant congenital abnormalities

          -  Presence of a pneumothorax prior to enrollment

          -  Hemodynamic instability due to sepsis or hemorrhage

          -  Inability to obtain parental consent

          -  Shortage of suitable equipment

          -  Infants who were intubated solely for surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayala Gover, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayala Gover, MD</last_name>
    <phone>972-528-396948</phone>
    <email>ayalagover@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayala Gover, MD</last_name>
      <phone>972-52-396948</phone>
      <email>ayalagover@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carmel Medical Center</investigator_affiliation>
    <investigator_full_name>Ayala Gover</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

